Until now, several lifestyle and pharmacological interventions, namely insulin, acarbose, pioglitazone, rosiglitazone, have been previously associated with reversal of inflammation, lipid peroxidation and TX-dependent platelet activation in the settings of obesity or T2DM, in parallel with a variable decrease in body weight and/or improvement in metabolic control [2,3,5,6,17,52,53,54]. This evidence concerns the gene INS and obesity disorder.